Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 compass mutant cancer
AssigneeNorthwestern University
InventorsAli Shilatifard, Zibo Zhao
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for treating a subject comprising the administration of an effective amount of a nucleotide synthesis inhibitor to a subject in need of treatment for a MLL3/4 COMPASS deficient cancer or a MLL3/4 loss of function mutation.
Claims23
A method for treatment of a subject having a MLL3/4 COMPASS deficient cancer, the method comprising administering to the subject an effective amount of a nucleotide synthesis inhibitor.
A method for treatment of a subject having a MLL3/4 loss of function mutation, the method comprising administering the subject an effective amount of a nucleotide synthesis inhibitor.
A method for the treatment of a subject, the method comprising obtaining a sample from a subject;
- testing the sample for the presence of a biomarker for a MLL3/4 COMPASS deficient cancer;
- and administering an effective amount of a nucleotide synthesis inhibitor to the subject if the sample tests positive for the biomarker.
Dependencies are inferred from the claim text.